RPL17 and lung carcinoma: This may be related to the fact that PD-1/PD-L1 inhibitor chemotherapy combined with Lung Cancer Fang No. 1 therapy can inhibit tumor cell proliferation and metastasis by inhibiting tumor angiogenesis [27–29].